Inventor · disambiguated record
Hai-Tsang Huang
Also filed as: HUANG HAI · HUANG HAI-TSANG
9 granted patents·7 pending applications·19 citations·filing 2016–2025
81Inventor score
Files withDANA FARBER CANCER INST INC7HENAN MEDINNO PHARMACEUTICAL TECH CO LTD4MEDINNO PHARMACEUTICAL TECH ZHUHAI CO LTD3BROAD INST INC1SHENZHEN KANGSU PHARMACEUTICAL TECH CO LTD1
Top patents by PatentIndex Score
16 records- 0194US10544138B2Tricyclic kinase inhibitors of MELK and methods of useDANA FARBER CANCER INST INC·Filed 2016·Granted Jan 28, 2020·12 cites·20 claims
- 0288US10925967B2Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Feb 23, 2021·4 cites·3 claims
- 0384US11730818B2Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2020·Granted Aug 22, 2023·1 cites·14 claims
- 0477US12329821B2Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2023·Granted Jun 17, 2025·0 cites·21 claims
- 0574US11629148B2Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitorsHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2021·Granted Apr 18, 2023·1 cites·16 claims
- 0672US10842878B2Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Nov 24, 2020·1 cites·24 claims
- 0767US2025084453A1Systems, compositions and methods for identifying e3 ligase substrates by ubiquitin biotinylationBROAD INST INC·Filed 2024·Application pending·0 cites
- 0858US12180215B2Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitorsHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2023·Granted Dec 31, 2024·0 cites·19 claims
- 0955US10925868B2Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Feb 23, 2021·0 cites·19 claims
- 1053US2023374025A1Fgfr inhibitor compound and use thereofSHENZHEN KANGSU PHARMACEUTICAL TECH CO LTD·Filed 2023·Application pending·0 cites
- 1153US2025387388A1Compound as trk inhibitor and/or ret inhibitor and use thereofMEDINNO PHARMACEUTICAL TECH ZHUHAI CO LTD·Filed 2023·Application pending·0 cites
- 1253US2025215017A1TGF-ß INHIBITOR COMPOUND AND USE THEROFMEDINNO PHARMACEUTICAL TECH ZHUHAI CO LTD·Filed 2025·Application pending·0 cites
- 1352US2025179094A1Tgf-b inhibitor compound and use thereofMEDINNO PHARMACEUTICAL TECH ZHUHAI CO LTD·Filed 2025·Application pending·0 cites
- 1449US2024317760A1Trk kinase inhibitor compound and use thereofHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2022·Application pending·0 cites
- 1544US10875844B2Salicylate inhibitors of MELK and methods of useDANA FARBER CANCER INST INC·Filed 2016·Granted Dec 29, 2020·0 cites·13 claims
- 1640US2023192656A1Fgfr inhibitor compound and use thereofHENAN MEDINNO PHARMACEUTICAL TECH CO LTD·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hai-Tsang Huang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →